99 related articles for article (PubMed ID: 20417092)
1. Inter-observer agreement between dermatologists and oncologists in assessing dermatological toxicities in patients with metastatic colorectal cancer treated by cetuximab-based chemotherapies: a pilot comparative study.
Duffour J; Thézenas S; Dereure O; Garcin A; Caron J; Samalin E; Portales F; Fiess C; Chalbos P; Gestin-Boyer C; Ychou M; Guillot B
Eur J Cancer; 2010 Dec; 46(18):3169-74. PubMed ID: 20417092
[TBL] [Abstract][Full Text] [Related]
2. Cetuximab and circadian chronomodulated chemotherapy as salvage treatment for metastatic colorectal cancer (mCRC): safety, efficacy and improved secondary surgical resectability.
Lévi F; Karaboué A; Gorden L; Innominato PF; Saffroy R; Giacchetti S; Hauteville D; Guettier C; Adam R; Bouchahda M
Cancer Chemother Pharmacol; 2011 Feb; 67(2):339-48. PubMed ID: 20401611
[TBL] [Abstract][Full Text] [Related]
3. Cetuximab given every 2 weeks plus irinotecan is an active and safe option for previously treated patients with metastatic colorectal cancer.
Roca JM; Alonso V; Pericay C; Escudero P; Salud A; Losa F; López LJ; Guasch I; Méndez M; Quintero-Aldana G; Grande C; Vicente P; Arrivi A; Martin C; Moreno I; García P; Antón I; Constenla M; Yubero A; Cirera L;
Chemotherapy; 2010; 56(2):142-6. PubMed ID: 20407241
[TBL] [Abstract][Full Text] [Related]
4. Nuclear factor-kB tumor expression predicts response and survival in irinotecan-refractory metastatic colorectal cancer treated with cetuximab-irinotecan therapy.
Scartozzi M; Bearzi I; Pierantoni C; Mandolesi A; Loupakis F; Zaniboni A; Catalano V; Quadri A; Zorzi F; Berardi R; Biscotti T; Labianca R; Falcone A; Cascinu S
J Clin Oncol; 2007 Sep; 25(25):3930-5. PubMed ID: 17761976
[TBL] [Abstract][Full Text] [Related]
5. [Acneiform skin eruption in patients with metastatic colorectal carcinoma].
Gethöffer K; Schneider LA; Peters T; Weber L; Scharffetter-Kochanek K
Hautarzt; 2006 Jul; 57(7):628-31. PubMed ID: 16034631
[No Abstract] [Full Text] [Related]
6. Management of cutaneous side-effects of cetuximab therapy in patients with metastatic colorectal cancer.
Ocvirk J; Cencelj S
J Eur Acad Dermatol Venereol; 2010 Apr; 24(4):453-9. PubMed ID: 19793151
[TBL] [Abstract][Full Text] [Related]
7. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer.
Cunningham D; Humblet Y; Siena S; Khayat D; Bleiberg H; Santoro A; Bets D; Mueser M; Harstrick A; Verslype C; Chau I; Van Cutsem E
N Engl J Med; 2004 Jul; 351(4):337-45. PubMed ID: 15269313
[TBL] [Abstract][Full Text] [Related]
8. Phase II study of combination chemotherapy with biweekly cetuximab and irinotecan for pre-treated metastatic colorectal cancer harboring wild-type KRAS.
Shitara K; Yokota T; Takahari D; Shibata T; Ura T; Komatsu Y; Yuki S; Yoshida M; Takiuchi H; Utsunomiya S; Yatabe Y; Muro K
Jpn J Clin Oncol; 2010 Jul; 40(7):699-701. PubMed ID: 20304778
[TBL] [Abstract][Full Text] [Related]
9. A phase II study of cetuximab/irinotecan in patients with heavily pretreated metastatic colorectal cancer: predictive value of early specific toxicities.
Gamucci T; Nelli F; Cianci G; Grassi G; Moscetti L; Sperduti I; Zeuli M; Cortesi E; D'Auria G; Pollera CF
Clin Colorectal Cancer; 2008 Jul; 7(4):273-9. PubMed ID: 18650196
[TBL] [Abstract][Full Text] [Related]
10. Best practices in the management of toxicities related to anti-EGFR agents for metastatic colorectal cancer.
Ouwerkerk J; Boers-Doets C
Eur J Oncol Nurs; 2010 Sep; 14(4):337-49. PubMed ID: 20580896
[TBL] [Abstract][Full Text] [Related]
11. [Cutaneous toxicity associated with cetuximab treatment in metastatic colorectal cancer].
Rodríguez-Murphy E; Villanueva-Herraiz S; Ortega-García MP; Pérez-Feliu A; López-Montenegro Soria MA; Camps-Herrero C
Farm Hosp; 2011; 35(3):114-20. PubMed ID: 21497124
[TBL] [Abstract][Full Text] [Related]
12. [The efficacy of cetuximab for metastatic colorectal cancer].
Katsumoto Y; Aritake N; Endoh A
Gan To Kagaku Ryoho; 2010 Nov; 37(12):2523-5. PubMed ID: 21224627
[TBL] [Abstract][Full Text] [Related]
13. Detection of KRAS oncogene in peripheral blood as a predictor of the response to cetuximab plus chemotherapy in patients with metastatic colorectal cancer.
Yen LC; Yeh YS; Chen CW; Wang HM; Tsai HL; Lu CY; Chang YT; Chu KS; Lin SR; Wang JY
Clin Cancer Res; 2009 Jul; 15(13):4508-13. PubMed ID: 19549774
[TBL] [Abstract][Full Text] [Related]
14. EPIC: phase III trial of cetuximab plus irinotecan after fluoropyrimidine and oxaliplatin failure in patients with metastatic colorectal cancer.
Sobrero AF; Maurel J; Fehrenbacher L; Scheithauer W; Abubakr YA; Lutz MP; Vega-Villegas ME; Eng C; Steinhauer EU; Prausova J; Lenz HJ; Borg C; Middleton G; Kröning H; Luppi G; Kisker O; Zubel A; Langer C; Kopit J; Burris HA
J Clin Oncol; 2008 May; 26(14):2311-9. PubMed ID: 18390971
[TBL] [Abstract][Full Text] [Related]
15. Can the addition of cetuximab to irinotecan improve outcome in colorectal cancer?
Saltz LB
Nat Clin Pract Oncol; 2005 Jan; 2(1):20-1. PubMed ID: 16264850
[No Abstract] [Full Text] [Related]
16. Efficacy and skin toxicity management with cetuximab in metastatic colorectal cancer: outcomes from an oncologic/dermatologic cooperation.
Racca P; Fanchini L; Caliendo V; Ritorto G; Evangelista W; Volpatto R; Milanesi E; Ciorba A; Paris M; Facilissimo I; Macripò G; Clerico M; Ciuffreda L
Clin Colorectal Cancer; 2008 Jan; 7(1):48-54. PubMed ID: 18279577
[TBL] [Abstract][Full Text] [Related]
17. Randomized phase II trial of cetuximab, bevacizumab, and irinotecan compared with cetuximab and bevacizumab alone in irinotecan-refractory colorectal cancer: the BOND-2 study.
Saltz LB; Lenz HJ; Kindler HL; Hochster HS; Wadler S; Hoff PM; Kemeny NE; Hollywood EM; Gonen M; Quinones M; Morse M; Chen HX
J Clin Oncol; 2007 Oct; 25(29):4557-61. PubMed ID: 17876013
[TBL] [Abstract][Full Text] [Related]
18. [Cetuximab].
Takiuchi H
Gan To Kagaku Ryoho; 2007 Aug; 34(8):1192-5. PubMed ID: 17687200
[TBL] [Abstract][Full Text] [Related]
19. Topical vitamin K1 may not be effective in preventing acneiform rash during cetuximab treatment in patients with metastatic colorectal cancer.
Jo JC; Hong YS; Kim KP; Lee JL; Kim HJ; Lee MW; Lim SB; Yu CS; Kim JC; Kim JH; Kim TW
Eur J Dermatol; 2013; 23(1):77-82. PubMed ID: 23238388
[TBL] [Abstract][Full Text] [Related]
20. Reduced incidence of infusion-related reactions in metastatic colorectal cancer during treatment with cetuximab plus irinotecan with combined corticosteroid and antihistamine premedication.
Siena S; Glynne-Jones R; Adenis A; Thaler J; Preusser P; Aguilar EA; Aapro MS; Loos AH; Esser R; Wilke H
Cancer; 2010 Apr; 116(7):1827-37. PubMed ID: 20143444
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
